LSN e.V. introduces: TIEFENBACHER GROUP
Oliver Schrader, Managing Director @TIEFENBACHER GROUP: “We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before.”
From a distributor of Active Pharmaceutical Ingredients (APIs) to a purpose-driven healthcare company with a global footprint
Founded in 1963 as the world’s first exclusive distributor for active pharmaceutical ingredients TIEFENBACHER GROUP has been grown into a leading healthcare company with a turnover of more than 300 Mio € and over 800 employees at three locations worldwide. Two core business units build the fundament of TIEFENBACHER GROUP´s growing B2B business: pharmaceutical raw materials and finished dosage forms (FDF).
TIEFENBACHER API offers a full and complementary range of high-quality raw materials and value-added services. The company is a pioneer in supplying the European pharmaceutical industry with the finest APIs of distinguished manufacturers around the globe. Today a portfolio of 600+ APIs is distributed to more than 250 customers in 30+ European countries. Thereby Tiefenbacher API´s employees are daily driven by delivering better access, better quality, and a better supply of APIs.
AET – TIEFENBACHER PHARMACEUTICALS (TIEFENBACHER GROUP´s FDF business unit) provides solutions throughout the entire life cycle of a pharmaceutical product: including the development, manufacturing, and registering of innovative as well as generic drugs for B2B customers and distribution partners. The world´s most trusted brands count on TIEFENBACHER´s high excellence in creating best-in-class-dossiers and the ability to manage complex launches in over 80 countries worldwide. Own laboratories and manufacturing sites in India and Cyprus make it possible to build up efficient supply chains resulting in best value for money. Furthermore, TIEFENBACHER PHARMACEUTICALS is committed to drive for growth and innovation by a well-defined portfolio of highly potent drug formulations as well as combining medicines with e-health solutions.
Dr. Kristian Ruepp, Managing Director @TIEFENBACHER GROUP: “Thanks to our international knowledge in R&D and regulatory affairs, we enable our customers to enter global markets as fast as possible – making our high-quality medicines more affordable and more available for patients worldwide.”
Zweiter ERC Synergy Grant für das UKE
Crown Bioscience übernimmt Service-Sparte von Indivumed
Maike Frye hat Tierschutzprofessur am UKE übernommen
apoBank unterzeichnet die UN PRI
Biotech & Pharma, Förderung & Wettbewerb, MedTech